PMID: 6112387May 2, 1981Paper

Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis

Lancet
S P HanleyS Heptinstall

Abstract

The capacity of venous tissue for prostacyclin synthesis was determined in 68 patients undergoing surgery for removal of varicose veins. A single dose of aspirin (81 mg or 300 mg) taken 14 h preoperatively strongly inhibited its synthesis, and the effect of 300 mg was still evident 48 h after ingestion. A single dose of 40 mg aspirin taken 14 h preoperatively had no effect on prostacyclin synthesis. The capacity of blood platelets to synthesise thromboxane (measured as malondialdehyde) was determined in volunteers before and at various times after ingestion of 300 mg or 40 mg aspirin. Both doses had an inhibitory effect that lasted for at least 96 h. The length of time for which the amount of thromboxane synthesised was insufficient to support platelet aggregation and the platelet release reaction depended on both the donor and the dose of aspirin. If prostacyclin and thromboxane are important in the pathogenesis of thrombosis, then doses of aspirin much lower than those used previously should be tested. The long-lasting effect of 300 mg aspirin on both venous tissue and platelets indicates that this dose is unlikely to produce a favourable prostacyclin/thromboxane balance.

References

Sep 1, 1978·Pharmacological Research Communications·M BasistaR J Gryglewski
Mar 1, 1979·The Journal of Clinical Investigation·E A Jaffe, B B Weksler
Feb 1, 1978·The Journal of Clinical Investigation·J W BurchP W Majerus
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·G J RothP W Majerus
Sep 1, 1975·The Journal of Clinical Investigation·G J Roth, P W Majerus
Jun 23, 1971·Nature: New Biology·J B Smith, A L Willis
Jan 12, 1980·Lancet·E M Hoogendijk, J W ten Cate
Feb 16, 1980·Lancet·F I ParetiJ B Smith
Dec 1, 1980·Circulation·P C Elwood, P M Sweetnam

❮ Previous
Next ❯

Citations

Jan 1, 1997·Cardiovascular Drugs and Therapy·W Förster, J R Parratt
Jan 1, 1984·European Journal of Clinical Pharmacology·E NiteliusA Melander
Jan 1, 1983·European Journal of Clinical Pharmacology·E NuottoU Lamminsivu
Jan 1, 1986·Lung·S P Hanley
Dec 7, 2013·Journal of Cardiovascular Translational Research·Mark R Thomas, Robert F Storey
Oct 16, 1989·Clinica Chimica Acta; International Journal of Clinical Chemistry·T K LeeZ S Huang
Jan 1, 1983·Thrombosis Research. Supplement·J J Thiessen
Oct 1, 1982·Prostaglandins, Leukotrienes, and Medicine·J E TookeJ A Davies
Nov 1, 1983·Prostaglandins, Leukotrienes, and Medicine·J W McDonaldC P Hayward
Nov 1, 1985·Prostaglandins, Leukotrienes, and Medicine·S P Hanley, J Bevan
Jun 1, 1985·Prostaglandins, Leukotrienes, and Medicine·P MadernaE Tremoli
Jan 1, 1988·General Pharmacology·A HeviaA Reche
Jan 1, 1989·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·T J Hartney
Oct 12, 1985·Lancet·G D Angelini, I M Breckenridge
Mar 15, 1986·Lancet
Mar 7, 2000·Journal of Pharmaceutical and Biomedical Analysis·K A Sagar, M R Smyth
Feb 1, 1985·Journal of the American College of Cardiology·J L MartinV P Addonizio
Jan 8, 1983·British Medical Journal·P J SwindellC E Spence
Feb 9, 1985·British Medical Journal·J R Hampton
Sep 14, 1985·British Medical Journal·R D Eastham
Feb 25, 1989·BMJ : British Medical Journal·P J PrichardC J Hawkey
Nov 1, 1982·British Heart Journal·J R Mitchell
Jun 1, 1982·The Journal of Clinical Investigation·P PatrignaniC Patrono
Nov 1, 1983·The Journal of Clinical Investigation·P W Majerus
Mar 6, 2008·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Avshalom ShalomMelvyn Westreich
Apr 1, 1985·Thrombosis Research·W D Zwierzina, F Kunz
Mar 19, 1983·Lancet
Nov 1, 1988·Prostaglandins, Leukotrienes, and Essential Fatty Acids·H SinzingerJ O'Grady
Sep 1, 1982·Thrombosis Research·C A JacksonF E Preston
Aug 15, 1982·Thrombosis Research·F E PrestonC J Stoddard
Aug 1, 1987·International Journal of Oral and Maxillofacial Surgery·P J Chapman, A W Macleod
Apr 14, 2009·The American Journal of Cardiology·M Haris U UsmanMichael D Ezekowitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.